首页> 美国卫生研究院文献>other >KIR HLA and IL28B Variant Predict Response to Antiviral Therapy in Genotype 1 Chronic Hepatitis C Patients in Japan
【2h】

KIR HLA and IL28B Variant Predict Response to Antiviral Therapy in Genotype 1 Chronic Hepatitis C Patients in Japan

机译:KIRHLA和IL28B变异预测日本基因型1型慢性丙型肝炎患者对抗病毒治疗的反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Natural killer cell responses play a crucial role in virus clearance by the innate immune system. Although the killer immunoglobulin-like receptor (KIR) in combination with its cognate human leukocyte antigen (HLA) ligand, especially KIR2DL3-HLA-C1, is associated with both treatment-induced and spontaneous clearance of hepatitis C virus (HCV) infection in Caucasians, these innate immunity genes have not been fully clarified in Japanese patients. We therefore investigated 16 KIR genotypes along with HLA-B and -C ligands and a genetic variant of interleukin (IL) 28B (rs8099917) in 115 chronic hepatitis C genotype 1 patients who underwent pegylated-interferon-α2b (PEG-IFN) and ribavirin therapy. HLA-Bw4 was significantly associated with a sustained virological response (SVR) to treatment (P = 0.017; odds ratio [OR] = 2.50, ), as was the centromeric A/A haplotype of KIR (P = 0.015; OR 3.37). In contrast, SVR rates were significantly decreased in patients with KIR2DL2 or KIR2DS2 (P = 0.015; OR = 0.30, and P = 0.025; OR = 0.32, respectively). Multivariate logistic regression analysis subsequently identified the IL28B TT genotype (P = 0.00009; OR = 6.87, 95% confidence interval [CI] = 2.62 - 18.01), KIR2DL2/HLA-C1 (P = 0.014; OR = 0.24, 95% CI = 0.08 - 0.75), KIR3DL1/HLA-Bw4 (P = 0.008, OR = 3.32, 95% CI = 1.37 - 8.05), and white blood cell count at baseline (P = 0.009; OR = 3.32, 95% CI = 1.35 - 8.16) as independent predictive factors of an SVR. We observed a significant association between the combination of IL28B TT genotype and KIR3DL1-HLA-Bw4 in responders (P = 0.0019), whereas IL28B TT along with KIR2DL2-HLA-C1 was related to a non-response (P = 0.0067). In conclusion, combinations of KIR3DL1/HLA-Bw4, KIR2DL2/HLA-C1, and a genetic variant of the IL28B gene are predictive of the response to PEG-IFN and ribavirin therapy in Japanese patients infected with genotype 1b HCV.
机译:自然杀伤细胞反应在先天免疫系统清除病毒中起关键作用。尽管杀伤性免疫球蛋白样受体(KIR)及其相关的人类白细胞抗原(HLA)配体(尤其是KIR2DL3-HLA-C1)与高加索人丙型肝炎病毒感染的治疗诱导和自发清除有关,这些先天免疫基因尚未在日本患者中完全阐明。因此,我们在115名接受聚乙二醇干扰素-α2b(PEG-IFN)和利巴韦林治疗的慢性丙型肝炎基因1型患者中调查了16种KIR基因型以及HLA-B和-C配体以及白介素(IL)28B(rs8099917)的遗传变异治疗。 HLA-Bw4与治疗的持续病毒学应答(SVR)显着相关(P = 0.017;优势比[OR] = 2.50,),KIR的着丝粒A / A单倍型也是如此(P = 0.015; OR 3.37)。相比之下,KIR2DL2或KIR2DS2患者的SVR率显着降低(分别为P = 0.015; OR = 0.30; P = 0.025; OR = 0.32)。多元Logistic回归分析随后确定了IL28B TT基因型(P = 0.00009; OR = 6.87,95%置信区间[CI] = 2.62-18.01),KIR2DL2 / HLA-C1(P = 0.014; OR = 0.24,95%CI = 0.08-0.75),KIR3DL1 / HLA-Bw4( P = 0.008,OR = 3.32、95%CI = 1.37-8.05)和基线白血球计数( P = 0.009; OR = 3.32,95%CI = 1.35-8.16)是SVR的独立预测因素。我们观察到 IL28B TT基因型与 KIR3DL1 - HLA-Bw4 的组合在应答者( P = 0.0019),而 IL28B TT和 KIR2DL2-HLA-C1 与无响应相关( P = 0.0067)。总之, KIR3DL1 / HLA-Bw4 KIR2DL2 / HLA-C1 IL28B 基因的遗传变异的组合可预测基因型1b HCV感染的日本患者对PEG-IFN和病毒唑治疗的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号